Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482171 | 0.88 | NPC1 (0.37) | TRPA1ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL16954405 | 0.71 | TRPA1 (0.61) | TRPA1ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL5696610 | 0.69 | HTR1D (0.38) | ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL16956159 | 0.67 | ALDH1A1 (0.44) | TRPA1ALDH1A1TSHRTDP1 | |
| SCHEMBL11672393 | 0.66 | CYP2A6 (0.48) | ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL7133957 | 0.66 | TP53 (0.33) | ALDH1A1TP53TDP1 | |
| SCHEMBL14890 | 0.65 | ALDH1A1 (0.58) | ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL30620702 | 0.65 | ALDH1A1 (0.58) | ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL8759091 | 0.62 | CSNK2A1 (0.49) | ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL28732534 | 0.62 | ALDH1A1 (0.43) | ALDH1A1TSHRTP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186717-B2 | Pyrrolidine derivatives as Factor Xa inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050107379-A1 | Pyrrolidine derivatives as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107379-A1 | Pyrrolidine derivatives as factor xa inhibitors | TFPI, F2, SERPINC1 | TRPA1 4511/4885ALDH1A1 1542/4885TSHR 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.